ClinicalTrials.gg
CompletedNCT02392234Updated Jun 12, 2018Results posted

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

A Phase 3 interventional study of VX-661/Ivacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 94 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-06-12.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
7th of 43
248 · median 100
Started
2015
with 4 others
Phase 3
25 of 43
none open now
Registered
5th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 7th largest by enrollment, is one of 5 that started in 2015, is one of 25 in phase 3, and was the 5th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF) who are heterozygous for F508del-CFTR allele and a second allele with a CFTR mutation predicted to have residual function.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heterozygous for F508del-CFTR and a second allele with a CFTR mutation predicted to have residual function
  • (FEV1) greater than or equal to (≥) 40 percent (%) and less than or equal to (≤) 90% of predicted normal for age, sex, and height during screening
  • Sweat chloride value ≥60 millimole per liter (mmol/L) during screening OR as documented in the participant's medical record
  • Stable CF disease as judged by the investigator

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
  • An acute upper or lower respiratory infection, pulmonary exacerbation
  • History of solid organ or hematological transplantation
  • Ongoing or prior participation in an drug study (including studies investigating VX-661, lumacaftor [VX-809], and/or ivacaftor) within 30 days of screening
  • Pregnant and nursing females
  • Sexually active participants of who are not willing to follow the requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    VX-661/Ivacaftor combination

    Drug: VX-661/Ivacaftor · Drug: Ivacaftor · Drug: Placebo matched to Ivacaftor

  • Experimental
    Ivacaftor monotherapy

    Drug: Ivacaftor · Drug: Placebo matched to VX-661/ ivacaftor

  • Placebo comparator
    Placebo

    Drug: Placebo matched to VX-661/ ivacaftor · Drug: Placebo matched to Ivacaftor

Interventions

  • DrugVX-661/Ivacaftor

    Drug pages: Tezacaftor · Ivacaftor

    Fixed dose combination tablet, oral use

    Also known as: VX-661+VX-770

  • Tablet, oral use

    Also known as: IVA, VX-770

  • DrugPlacebo matched to VX-661/ ivacaftor

    Fixed dose combination tablet, oral use

  • DrugPlacebo matched to Ivacaftor

    Tablet, oral use

06

What researchers measure

Primary outcomes

  1. Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Week 4 and Week 8 of each treatment period

Secondary outcomes

  1. Absolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8

    The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Week 4 and Week 8 of each treatment period

  2. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 28

  3. Relative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Week 4 and Week 8 of each treatment period

  4. Absolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8

    Time frame: Baseline, Week 4 and Week 8 of each treatment period

  5. Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661), IVA and IVA Metabolite (M1 IVA) After Administration of VX-661/IVA Combination Therapy

    Time frame: Pre-morning dose on Week 8 of each treatment period

  6. Ctrough of IVA and IVA Metabolite (M1 IVA) After Administration of IVA Monotherapy

    Time frame: Pre-morning dose on Week 8 of each treatment period

07

Results

Posted Jun 12, 2018

Participant flow

A total of 248 participants were enrolled. Out of which, 246 received at least 1 dose of study drug were included in safety set and 244 participants who carried intended cystic fibrosis transmembrane conductance regulator (CFTR) mutations were included in Full analysis set.

Treatment Period 1 (8 Weeks)
Participant flow — Treatment Period 1 (8 Weeks)
MilestoneFirst VX-661/IVA, Then IVAFirst VX-661/IVA, Then PlaceboFirst IVA, Then PlaceboFirst IVA, Then VX- 661/IVAFirst Placebo, Then VX- 661/IVAFirst Placebo, Then IVA
Started414340424141
Treated414339424041
Completed384338413738
Not completed302143
Withdrew: Adverse event101011
Withdrew: Withdrawal by subject000020
Withdrew: Lost to follow-up000001
Withdrew: Pregnancy100100
Withdrew: Noncompliance000001
Withdrew: Other100000
Withdrew: Randomized but not treated001010
Treatment Period 2 (8 Weeks)
Participant flow — Treatment Period 2 (8 Weeks)
MilestoneFirst VX-661/IVA, Then IVAFirst VX-661/IVA, Then PlaceboFirst IVA, Then PlaceboFirst IVA, Then VX- 661/IVAFirst Placebo, Then VX- 661/IVAFirst Placebo, Then IVA
Started384338413738
Completed374338413738
Not completed100000
Withdrew: Adverse event100000

Outcome measures

PrimaryAbsolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Week 4 and Week 8 of each treatment period
Reported as:
Least squares mean · percentage of predicted FEV1
Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8
percentage of predicted FEV1PlaceboIvacaftorVX-661/IVA
Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8-0.3 (-1.2 to 0.6)4.4 (3.5 to 5.3)6.5 (5.6 to 7.3)
Statistical analysis
  • Placebo vs Ivacaftor · Linear Mixed Effects Model · p = < 0.0001 · Least squares (ls) mean difference: 4.7 · 95% CI 3.7 to 5.8
  • Placebo vs VX-661/IVA · Linear Mixed Effects Model · p = < 0.0001 · Ls mean difference: 6.8 · 95% CI 5.7 to 7.8
SecondaryAbsolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8

The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Week 4 and Week 8 of each treatment period
Reported as:
Least squares mean · units on a scale
Absolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8
units on a scalePlaceboIvacaftorVX-661/IVA
Absolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8-1.0 (-2.9 to 1.0)8.7 (6.8 to 10.7)10.1 (8.2 to 12.1)
Statistical analysis
  • Placebo vs Ivacaftor · Linear Mixed Effects Model · p = <0.0001 · Ls mean difference: 9.7 · 95% CI 7.2 to 12.2
  • Placebo vs VX-661/IVA · Linear Mixed Effects Model · p = <0.0001 · Ls mean difference: 11.1 · 95% CI 8.7 to 13.6
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 28
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPlaceboIvacaftorVX-661/IVA
Participants with any AEs126114117
Participants with SAEs14108
SecondaryRelative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Week 4 and Week 8 of each treatment period
Reported as:
Least squares mean · percent change
Relative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8
percent changePlaceboIvacaftorVX-661/IVA
Relative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8-0.2 (-1.7 to 1.4)7.9 (6.4 to 9.4)11.2 (9.7 to 12.7)
Statistical analysis
  • Placebo vs Ivacaftor · Linear Mixed Effects Model · p = <0.0001 · Ls mean difference: 8.1 · 95% CI 6.3 to 9.9
  • Placebo vs VX-661/IVA · Linear Mixed Effects Model · p = <0.0001 · Ls mean difference: 11.4 · 95% CI 9.6 to 13.2
SecondaryAbsolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8
Time frame:
Baseline, Week 4 and Week 8 of each treatment period
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Absolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8
millimoles per liter (mmol/L)PlaceboIvacaftorVX-661/IVA
Absolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8-0.4 (-2.3 to 1.5)-4.9 (-6.7 to -3.0)-9.9 (-11.8 to -8.0)
Statistical analysis
  • Placebo vs Ivacaftor · Linear Mixed Effects Model · p = <0.0001 · Ls mean difference: -4.5 · 95% CI -6.7 to -2.3
  • Placebo vs VX-661/IVA · Linear Mixed Effects Model · p = <0.0001 · Ls mean difference: -9.5 · 95% CI -11.7 to -7.3
SecondaryTrough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661), IVA and IVA Metabolite (M1 IVA) After Administration of VX-661/IVA Combination Therapy
Time frame:
Pre-morning dose on Week 8 of each treatment period
Reported as:
Mean · nanogram per milliliter (ng/mL)
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661), IVA and IVA Metabolite (M1 IVA) After Administration of VX-661/IVA Combination Therapy
nanogram per milliliter (ng/mL)VX-661/IVA
VX-6612370 ± 1330
M1 VX-6615230 ± 1940
IVA909 ± 530
M1 IVA2010 ± 1050
SecondaryCtrough of IVA and IVA Metabolite (M1 IVA) After Administration of IVA Monotherapy
Time frame:
Pre-morning dose on Week 8 of each treatment period
Reported as:
Mean · ng/mL
Ctrough of IVA and IVA Metabolite (M1 IVA) After Administration of IVA Monotherapy
ng/mLIvacaftor
IVA696 ± 435
M1 IVA1550 ± 808

Adverse events

Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/162 (0%)14/162 (8.6%)87/162 (53.7%)
Ivacaftor0/157 (0%)10/157 (6.4%)54/157 (34.4%)
VX-661/IVA0/162 (0%)8/162 (4.9%)80/162 (49.4%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboIvacaftorVX-661/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations8/1626/1574/162
Blood creatine phosphokinase increasedInvestigations0/1622/1570/162
PneumoniaInfections and infestations2/1620/1570/162
HaemoptysisRespiratory, thoracic and mediastinal disorders2/1621/1570/162
Abdominal painGastrointestinal disorders2/1620/1570/162
Distal intestinal obstruction syndromeGastrointestinal disorders0/1621/1570/162
PancreatitisGastrointestinal disorders0/1621/1570/162
InfluenzaInfections and infestations0/1620/1571/162
Ankle fractureInjury, poisoning and procedural complications0/1620/1571/162
HeadacheNervous system disorders0/1620/1571/162
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboIvacaftorVX-661/IVA
CoughRespiratory, thoracic and mediastinal disorders30/16217/15723/162
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations25/16214/15719/162
HeadacheNervous system disorders13/16211/15718/162
HaemoptysisRespiratory, thoracic and mediastinal disorders12/16217/15712/162
FatigueGeneral disorders16/1627/15712/162
Sputum increasedRespiratory, thoracic and mediastinal disorders11/16212/15714/162
NasopharyngitisInfections and infestations5/1626/15713/162
DiarrhoeaGastrointestinal disorders10/1625/15713/162
PyrexiaGeneral disorders12/1622/1578/162
DyspnoeaRespiratory, thoracic and mediastinal disorders11/1623/1579/162

Baseline characteristics

The Full Analysis Set (FAS) was defined as all randomized subjects who carry the intended cystic fibrosis transmembrane conductance regulator (CFTR) mutations and had received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)First VX- 661/IVA, Then IVAFirst VX-661/IVA, Then PlaceboFirst IVA, Then PlaceboFirst IVA, Then VX- 661/IVAFirst Placebo, Then VX- 661/IVAFirst Placebo, Then IVATotal
<=18 years56755634
Between 18 and 65 years363733373435212
>=65 years0000202
Sex: Female, Male
Sex: Female, Male(Participants)First VX- 661/IVA, Then IVAFirst VX-661/IVA, Then PlaceboFirst IVA, Then PlaceboFirst IVA, Then VX- 661/IVAFirst Placebo, Then VX- 661/IVAFirst Placebo, Then IVATotal
Female232519212323134
Male181821211818114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)First VX- 661/IVA, Then IVAFirst VX-661/IVA, Then PlaceboFirst IVA, Then PlaceboFirst IVA, Then VX- 661/IVAFirst Placebo, Then VX- 661/IVAFirst Placebo, Then IVATotal
Hispanic or Latino1013229
Not Hispanic or Latino404339393739237
Unknown or Not Reported0000202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)First VX- 661/IVA, Then IVAFirst VX-661/IVA, Then PlaceboFirst IVA, Then PlaceboFirst IVA, Then VX- 661/IVAFirst Placebo, Then VX- 661/IVAFirst Placebo, Then IVATotal
American Indian or Alaska Native0000011
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American2000013
White394240423939241
More than one race0000000
Unknown or Not Reported0100203
08

Study locations

94 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Long Beach, California, United States
  • Oakland, California, United States
  • Palo Alto, California, United States
  • Sacramento, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • Gainesville, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Park Ridge, Illinois, United States
  • Iowa City, Iowa, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Lebanon, New Hampshire, United States
  • New York, New York, United States
  • Syracuse, New York, United States
  • Valhalla, New York, United States
  • Chapel Hill, North Carolina, United States
  • Akron, Ohio, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Toledo, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Sioux Falls, South Dakota, United States
  • Memphis, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Tyler, Texas, United States
  • Salt Lake City, Utah, United States
  • Norfolk, Virginia, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Adelaide, Australia
  • Melbourne, Australia
  • South Brisbane, Australia
  • Westmead, Australia
  • Gent, Belgium
  • Montreal, Canada
  • Quebec City, Canada
  • Toronto, Canada
  • Vancouver, Canada
  • Marseille cedex 20, Bouches-du-Rhone, France
  • Montpellier cedex 5, Herault, France
  • Rennes cedex 09, Ille Et Vilaine, France
  • Lille cedex, Nord, France
  • Paris cedex 14, Paris, France
  • Paris cedex 15, Paris, France
  • Bron, Rhone, France
  • Bordeaux Cedex, France
  • Muenchen, Bayern, Germany
  • Munchen, Bayern, Germany
  • Hannover, Niedersachsen, Germany
  • Essen, Nordrhein Westfalen, Germany
  • Jena, Thueringen, Germany
  • Berlin, Germany
  • Haifa, Israel
  • Jerusalem, Israel
  • Petach-Tikva, Israel
  • Ramat-Gan, Israel
  • Ancona, Italy
  • Milano, Italy
  • Orbassano, Italy
  • Potenza, Italy
  • Roma, Italy
  • Verona, Italy
  • Amsterdam, Netherlands
  • Den Haag, Netherlands
  • Rotterdam, Netherlands
  • Utrecht, Netherlands
  • Bern, Switzerland
  • St Gallen, Switzerland
  • Zuerich, Switzerland
  • Exeter, Devon, United Kingdom
  • London, Greater London, United Kingdom
  • Manchester, Greater Manchester, United Kingdom
  • Southampton, Hampshire, United Kingdom
  • Liverpool, Lancashire, United Kingdom
  • Glasgow, Strathclyde, United Kingdom
  • Leeds, West Yorkshire, United Kingdom
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗
  • Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3. PubMed 29099333 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2018, 1 year 4 months after primary completion. A results delay was requested in Feb 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2015
First posted
Mar 18, 2015
Start
Mar 2015
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Results delay requested
Feb 12, 2018
Results first posted
Jun 12, 2018
Last update
Jun 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02392234
Responsible party
Sponsor
First posted
Mar 18, 2015
Start date
Mar 2015
Primary completion
Feb 2017
Completion
Feb 2017
Results posted
Jun 12, 2018
Last update
Jun 12, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion